The authors examine how Pfizer and BioNTech’s encouraging vaccine announcement reshaped expectations across markets while emphasizing the uncertainty still surrounding efficacy, safety, and distribution. The 90% interim efficacy reading sparked a sharp rotation toward pandemic laggards, suggesting markets quickly repriced a potential normalization.
Following Recent Good News on the Vaccine, There Are the Facts, Perspective, and Still More Uncertainty
Bridgewater
Larry Cofsky, Richard Falkenrath
Article
1 Pages
Key Takeaways
Vaccine Results Surprise: Pfizer and BioNTech reported 90% interim efficacy versus expert expectations of roughly 50% to 70%, though questions around safety, durability, and distribution remained.
Pandemic Laggards Rally: Energy stocks gained 14.2% on November 9 despite remaining down 45.3% YTD, illustrating the sharp rotation toward areas hardest hit by COVID.
Growth Trade Reverses: Oil jumped 7.81% while gold fell 4.41% on November 9, reflecting a shift toward growth sensitive assets and away from pandemic beneficiaries.
Join our newsletter to have all of this content + Exclusive Newsletter Bonus Content delivered to your inbox every week
